The acquisition of the manufacturing license will be effected through the acquisition of equity in Tianda as well as transfer of certain technologies from Tianda.
Rosuvastatin was first marketed by Astrazeneca as Crestor in 2003 and is an effective statin to treat high cholesterol and related conditions.
Jinsheng Ren, chairman and CEO of Simcere, said: “We are delighted to join forces with Tianda to manufacture Rosuvastatin in China. We believe that we can help more heart disease patients in China benefit from this drug.”